Related Experiment Videos
Fluoxetine-induced plasticity in the rodent visual system
E F Bastos1, J L Marcelino, A R Amaral
1Departamento de Neurobiologia, Universidade Federal Fluminense, Caixa Postal 100180, Niteroi, CEP 24001-970, RJ, Brazil.
Insights
Fluoxetine, a selective serotonin reuptake inhibitor, enhances brain plasticity in developing rats. This drug promotes axonal growth and reorganization, particularly after retinal injury, suggesting therapeutic potential for neurological recovery.
Area of Science:
- Neuroscience
- Developmental Biology
- Pharmacology
Background:
- The retinotectal pathway is a model system for studying axonal development and plasticity.
- Selective serotonin reuptake inhibitors (SSRIs) like fluoxetine are known to affect neuronal function.
- Understanding how SSRIs influence neural development and repair is crucial for potential therapeutic applications.
Purpose of the Study:
- To investigate the effects of fluoxetine on the development of retinotectal axons.
- To examine fluoxetine's impact on lesion-induced plasticity in the retinotectal system.
- To determine if fluoxetine amplifies neuroplasticity following retinal damage in developing rats.
Main Methods:
- Neonatal rats were treated with fluoxetine or vehicle during critical developmental periods (PND 1-10 or PND 14-28).
- A retinal lesion was induced in some animals at PND 21.
- Horseradish peroxidase (HRP) tracing was used to map retinotectal projections in the intact eye.
Main Results:
- Chronic fluoxetine treatment expanded retinotectal terminal fields in unoperated rats.
- In rats with retinal lesions, fluoxetine significantly amplified axonal plasticity.
- Fluoxetine-treated animals showed substantial sprouting of uncrossed retinal axons into denervated tectal areas.
Conclusions:
- Fluoxetine promotes significant axonal rearrangements in the developing central nervous system.
- The drug amplifies neuroplasticity in response to retinal injury, even late in development.
- These findings highlight fluoxetine's potential to enhance neural repair mechanisms.
Abstract:
We studied the effect of fluoxetine, a selective serotonin reuptake inhibitor, in the development and lesion-induced plasticity of retinotectal axons in pigmented rats. Neonatal rats received a daily injection of either fluoxetine or vehicle from postnatal day 1 (PND 1) to PND 10 or from PND 14 to PND 28 (fluoxetine, 7.5 and 10.0 mg/kg, respectively). In the latter group, some animals received a single lesion at the temporal periphery of the left retina at PND 21. Unoperated animals were use as the control. At the end of the treatment, the animals received an intraocular injection of horseradish peroxidase (HRP) in the right (intact) eye to trace the uncrossed retinotectal pathway. Chronic fluoxetine treatment, induced, in unoperated rats, an expansion of the retinal terminal fields along the rostro-caudal axis of the tectum both in the PND 10 and PND 28 groups. Following a retinal lesion in the left eye at PND 21, the vehicle-treated group showed a small reorganization of the intact uncrossed projection. In this group only a few terminals were labeled invading the denervated tectal surface one-week after the lesion. Fluoxetine-treated animals on the other hand, showed a great amplification of plasticity with a conspicuous sprouting of the uncrossed retinal axons into denervated areas. The data suggest that fluoxetine induces extensive axonal rearrangements in neonatal and juvenile central nervous system and amplifies neuroplasticity following retinal lesions late in development.